The F-box protein β-TrCP associates with phosphorylated β-catenin and regulates its activity in the cell  by Hart, M. et al.
Brief Communication 207
The F-box protein β-TrCP associates with phosphorylated
β-catenin and regulates its activity in the cell
M. Hart*†, J-P. Concordet†‡, I. Lassot§, I. Albert*, R. del los Santos*, H. Durand§,
C. Perret‡, B. Rubinfeld*, F. Margottin§, R. Benarous§ and P. Polakis*
Defects in β-catenin regulation contribute to the
neoplastic transformation of mammalian cells.
Dysregulation of β-catenin can result from missense
mutations that affect critical sites of phosphorylation by
glycogen synthase kinase 3β (GSK3β). Given that
phosphorylation can regulate targeted degradation of
β-catenin by the proteasome, β-catenin might interact
with an E3 ubiquitin ligase complex containing an F-box
protein, as is the case for certain cell cycle regulators.
Accordingly, disruption of the Drosophila F-box protein
Slimb upregulates the β-catenin homolog Armadillo.
We reasoned that the human homologs of Slimb —
β-TrCP and its isoform β-TrCP2 (KIAA0696) — might
interact with β-catenin. We found that the binding of
β-TrCP to β-catenin was direct and dependent upon the
WD40 repeat sequences in β-TrCP and on
phosphorylation of the GSK3β sites in β-catenin.
Endogenous β-catenin and β-TrCP could be
coimmunoprecipitated from mammalian cells.
Overexpression of wild-type β-TrCP in mammalian cells
promoted the downregulation of β-catenin, whereas
overexpression of a dominant-negative deletion mutant
upregulated β-catenin protein levels and activated
signaling dependent on the transcription factor Tcf. In
contrast, β-TrCP2 did not associate with β-catenin. We
conclude that β-TrCP is a component of an E3 ubiquitin
ligase that is responsible for the targeted degradation
of phosphorylated β-catenin.
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Results and discussion
Yeast were cotransformed with plasmids expressing
β-TrCP [1] fused to the Gal4 DNA binding domain and
β-catenin fused to the Gal4 transactivation domain.
Expression of either plasmid alone did not result in trans-
activation of the β-galactosidase reporter gene whereas
expression of both resulted in high levels of activity
(Figure 1a). Mutations altering β-catenin residues Ser37
and Ser45 have been identified in human tumors [2–7]
and are known to retard the targeted degradation of
β-catenin in mammalian cells [8]. These mutants failed to
interact with β-TrCP, but retained their ability to bind to
a fragment of the adenomatous polyposis coli (APC) tumor
suppressor protein (Figure 1a). To test for an interaction
with the β-catenin amino-terminal region, we fused
β-TrCP, or its isoform β-TrCP2, to the LexA DNA
binding domain and fused amino acids 1–130 of β-catenin
to the Gal4 transactivation domain. A positive interaction
Figure 1
Yeast two-hybrid binding assays. (a) Yeast cotransformed with
plasmids expressing the indicated proteins fused to either the Gal4
DNA binding domain (DB) or the Gal4 activation domain (AD) were
maintained on media containing histidine (growth) and patches were
assayed for β-galactosidase activity (β-gal). Wild-type β-catenin
(β-catWT) or forms with Ser37 or Ser45 mutated were tested. APC2, a
fragment of APC, was a positive control for β-catenin binding.
(b) Yeast cotransformed with plasmids expressing the indicated fusion
proteins were grown on synthetic media containing histidine (+His),
tested for auxotrophic growth in media lacking histidine (–His) or
transferred to filters for β-galactosidase assays. S33/37N indicates a
double mutation of Ser33 and Ser37 to asparagine residues. Skp1
was a positive control for β-TrCP binding.
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between the fusion proteins is required for the production
of β-galactosidase and survival on conditional media. The
β-catenin 1–130 fragment interacted with β-TrCP but a
double mutation changing β-catenin residues Ser33 and
Ser37 ablated the interaction (Figure 1b). However,
β-catenin failed to interact with β-TrCP2 [9] even though,
like β-TrCP, it contains an F-box, WD40 repeats and is
80% identical to the Slimb protein.
To examine the interaction in mammalian cells, β-TrCP
with a Myc epitope tag was expressed in three different
cell lines and anti-Myc immunoprecipitates were probed
for β-catenin. Coimmunoprecipitation of β-catenin with
β-TrCP was seen in all three cell lines and the interaction
was greatly enhanced in both the Neuro2A and 293 cells
by pretreatment with the proteosomal inhibitor N-acetyl-
leucinyl-leucinyl-norleucinyl-H (ALLN; Figure 2a,b). It is
not clear why the interaction in SW480 cells was indepen-
dent of ALLN treatment, but the extremely slow turnover
of β-catenin in these cells [10] might circumvent the need
for a proteosomal inhibitor to establish a stable interaction.
As APC is involved in the regulation of β-catenin function
[10,11], we sought to determine whether APC remained
associated with β-catenin in the β-TrCP complex. Accord-
ingly, anti-Myc immunoprecipitates from 293 cells were
probed for both APC and β-catenin. Wild-type APC
protein was detected in the immunoprecipitates of full-
length β-TrCP, and ALLN enhanced the amount that was
coimmunoprecipitated (Figure 2c). We also tested dele-
tion mutants of β-TrCP and found that a fragment lacking
the F-box but containing WD40 repeats 1–7 (WD1–7)
associated with β-catenin but a similar fragment lacking
the first WD40 repeat (WD2–7) did not. Also, no associa-
tion was detected with fragments containing the F-box
without WD40 repeats (F-box) or the F-box with the first
repeat (FWD1). We also immunoprecipitated endogenous
β-TrCP from cells that were not transfected and detected
β-catenin in the immunoprecipitates (Figure 2d). 
These results suggested that a modification of β-catenin
that occurred in response to ALLN was responsible for
the enhanced binding to β-TrCP. Previous reports
demonstrating phosphorylation-dependent interaction of
substrates to their F-box proteins [12–15], and our finding
that mutations in β-catenin serine residues abrogate its
binding to β-TrCP, suggested that the modification might
involve phosphorylation. We examined this by phosphory-
lating purified recombinant β-catenin with GSK3β in vitro
and then tested its ability to bind to in vitro translated
β-TrCP. As a control we also tested a deletion mutant of
β-catenin that lacks 89 amino-terminal amino acids
(∆N-β-catenin) and therefore does not contain the critical
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Figure 2
Association of β-TrCP with β-catenin and
APC in mammalian cells. (a) An empty vector
or plasmid expressing Myc–βTrCP were
transfected into 293 cells that were left
untreated (–) or incubated for 4 h in 25 µM
ALLN (+). Anti-Myc immunoprecipitates were
analyzed for β-catenin (β-cat; top panels) or
Myc–βTrCP (bottom panels). (b) The
interaction between β-TrCP and β-catenin
was also tested in Neuro2A and SW480
cells. (c) Myc-tagged full-length βTrCP and
the indicated deletion mutants were
expressed in 293 cells and anti-Myc
immunoprecipitates were analyzed for APC
(top panel), β-catenin (middle panel), or the
Myc epitope (bottom panel). The positions of
the Myc-tagged fragments are indicated by
the white dots. (d) Lysates from untransfected
293 and Neuro2A cells were subjected to
immunoprecipitation with a rabbit polyclonal
antibody to β-TrCP (TrCP) or, as a control,
protein-A–Sepharose alone (PAS), and the
immunoprecipitates were analyzed for
β-catenin. The protein fragments of β-TrCP
contain the following amino acids: full-length
β-TrCP, 1–569; WD1–7, 241–569; WD2–7,
291–569; F-box, 1–247; FWD1, 1–306. 
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serine and threonine residues that affect β-catenin
turnover in cells [16]. One set of kinase reactions con-
tained [γ-32P]ATP to account for phosphate incorporation
and a second set of reactions, without radioactive ATP,
was used to assess subsequent binding of β-catenin to
β-TrCP. Only when GSK3β was included in the reaction
with full-length β-catenin was significant radiolabeling
observed following the kinase reaction (Figure 3). When
β-catenin was recovered from the nonradioactive kinase
reaction and tested for binding to β-TrCP, only the full-
length protein bound, and binding was greatly enhanced
by prior phosphorylation by GSK3β. Moreover, the low
level of binding observed with the nonphosphorylated
full-length β-catenin was reduced to background levels
following its pretreatment with phosphatase. 
The interaction of phosphorylated β-catenin with β-TrCP
suggested that β-TrCP might be involved in the regulation
of β-catenin levels in the cell. The amount of β-catenin was
examined by immunoblotting following overexpression of
β-TrCP or the F-box deletion mutant β-TrCP∆F, which
acts as a dominant negative in CD4 degradation mediated
by the HIV-1 protein Vpu [1]. Expression of increasing
amounts of full-length β-TrCP resulted in a concomitant
reduction in β-catenin, whereas expression of β-TrCP∆F
promoted β-catenin accumulation (Figure 4a). One of the
consequences of β-catenin stabilization is the enhancement
of signaling that occurs through its interaction with the
lymphocyte enhancer factor/T-cell factor (Lef/Tcf) family
of transcription factors [11]. To measure Lef/Tcf-depen-
dent transcription, a plasmid containing a multimerized
synthetic Tcf binding site fused to the luciferase reporter
gene was cotransfected into 293 cells with β-TrCP con-
structs or, as a positive control, the amino-terminal deletion
mutant of β-catenin. Very little transactivation occurred
with vector alone, whereas cotransfection of ∆N-β-catenin
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Figure 3
Association of β-TrCP and phosphorylated
β-catenin in vitro. (a) Kinase reactions were
performed with purified Glu–Glu-tagged full-
length β-catenin (β-cat), the amino-terminal
deletion mutant (∆N-β-cat) or no protein (NA)
in the presence of [γ-32P]ATP with or without
purified GSK3β (GSK). Phosphorylation was
examined by autoradiography. (b) Parallel
reactions were performed with GSK3β with or
without nonradioactive ATP, or with
phosphatase (Ptase), and the β-catenin
recovered by Glu–Glu immunoprecipitation
was tested for binding to in vitro translated
radiolabeled β-TrCP as assessed by
fluorography (top panel). The recovery of
β-catenin was assessed by immunoblotting
with anti-Glu–Glu antibody (bottom panel). 
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Figure 4
Effect of β-TrCP on β-catenin levels and 
Tcf-dependent transcriptional activation.
(a) Approximately 8 × 106 Hela cells were
transfected with the indicated amounts of
Myc–β-TrCP or the dominant-negative mutant
Myc–β-TrCP∆F or were not transfected (C).
After 24 h, cells were lysed and 50 µg total
protein from each lysate was immunoblotted
with antibody to β-catenin (β-cat; top panel) or
to Myc (lower panel). Staining of a nonspecific
protein (asterisk) indicates comparable
loading of total protein in each lane.
(b) Activation of Lef/Tcf-dependent
transcription was determined by
cotransfection of 293 cells with the wild-type
reporter Top-tk-Luci, or the mutant control
reporter Fop-tk-Luci, and either empty vector
(pcDNA3), full-length β-TrCP, or β-TrCP∆F.
∆N-β-catenin was used as a positive control,
and β-TrCP2 and the corresponding F-box
deletion mutant β-TrCP2∆F (generated by
deletion of amino acids 1–170) were also
tested. Luciferase activity was normalized to
Renilla luciferase activity produced by
cotransfection with RSV-Renilla luciferase.
Representative data from three independent
experiments are shown. 
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resulted in a strong activation of luciferase transcription
from the wild-type promotor, but not from the mutant pro-
motor (Figure 4b). Full-length β-TrCP had no effect on the
already low level of basal signaling, but the dominant-nega-
tive mutant β-TrCP∆F elicited a strong response similar to
that of ∆N-β-catenin. β-TrCP had no effect on basal signal-
ing although a mutant β-TrCP2 lacking the F-box domain
promoted a low level of luciferase transcription.
It is now apparent that β-catenin possesses signaling capa-
bilities that have consequences for cell growth control
[17–22]. Mutations that affect the sites of phosphorylation
by GSK3β [23] stabilize β-catenin in vivo, and these types
of mutations have recently been identified in a wide
variety of primary human cancers [2–8]. The crucial Ser33
and Ser37 residues in β-catenin are located in a DSGXXS
motif (in single-letter amino-acid code where X is any
amino acid) identical to that of the phosphorylated
Ser52/Ser56 Vpu residues required for Vpu-mediated CD4
degradation by the proteasome [1]. This same motif is also
present in the NFκB inhibitor IκB where phosphorylation
of these serines initiates the rapid degradation of IκB [24].
It was recently reported that β-TrCP is a component of
the E3 ubiquitin ligase that targets IκB for ubiquitination
[25]. Therefore, the DSGXXS motif might represent a
signal sequence that is common to a given subset of sub-
strates that rely upon β-TrCP for their targeted degrada-
tion. Here, we have shown that these sites of
phosphorylation are required for the association of β-
catenin with β-TrCP. Our previous finding that β-TrCP
interacts with a component of the SCF ubiquitin ligase
complex, Skp1 [1], suggests that β-TrCP is part of the
multimeric E3 ubiquitin ligase belonging to the SCF
family [12]. We propose that SCFβ-TrCP is responsible for
targeting phosphorylated β-catenin for ubiquitination and
thereby promoting its degradation in the proteosome. The
enhanced stability and signaling output that is observed
with oncogenic mutants of β-catenin might be explained
by their failure to interact with the SCFβ-TrCP complex. 
Supplementary material
A detailed description of cDNA constructs and additional methodologi-
cal details are published with this paper on the internet.
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Supplementary materials and methods
cDNA cloning and construction
A BglII–NotI fragment (nucleotides 940–1779) of a human β-TrCP
cDNA (accession number AA478504) was cloned into a modified
pcDNA3 vector (Invitrogen) containing a Myc epitope tag (pCAN-Myc).
This construct was designated WD2—7 (amino acids 291–569). A
ClaI–NotI fragment was isolated from a β-TrCP PCR fragment
(nucleotides 70–989) and subcloned into the pCAN-Myc vector to
generate FWD1 (amino acids 1–306). A full-length β-TrCP (amino
acids 1–569) was generated from WD2—7 and FWD1 and subcloned
as a ClaI–NotI fragment into pCAN-Myc. The WD1–7 (amino acids
241–569) and F-box (amino acids 1–247) constructs were PCR prod-
ucts (nucleotides 790–1779 and 70–810, respectively) that were sub-
cloned as ClaI–XbaI fragments into the ClaI and XbaI sites of
pCAN-Myc. The β-catenin constructs have been previously described
[S1]. pcDNA3 β-TrCP and pcDNA3 β-TrCP∆F have been described
elsewhere [S2], and β-TrCP2∆F was generated by deletion of amino
acids 1–170 by PCR and cloned into pcDNA3.
Expression and immunoprecipitation of β-TrCP 
Transfections of the indicated plasmids into the human embryonic
kidney cell line 293 and the SW480 colorectal cell line were performed
as previously described [S3]. Neuro2A cells were transfected accord-
ing to the protocol for 293 cells. Cells were lysed 48 h post-transfec-
tion with 0.4 ml Triton lysis buffer (20 mM Tris-HCl, pH 8.0, 1.0%
Triton X-100, 140 mM NaCl, 10% glycerol, 1 mM EGTA, 1.5 mM
MgCl2, 1 mM dithiothreitol, 1 mM sodium vanadate, 50 mM NaF, 1 mM
pefabloc, 10 µg/ml each of aprotinin, pepstatin and leupeptin) per
35 mm well of confluent cells and the β-TrCP proteins were immuno-
precipitated with antibody specific to the Myc epitope as described
previously [S4]. Rabbit polyclonal antibodies to β-catenin and APC
[S4] were used in all experiments except for the use of polyclonal anti-
β-catenin antibody C2206 (Sigma) for the experiment in Figure 4a. The
protease inhibitor ALLN was from Sigma. Modulation of β-catenin
levels was monitored after transfection of HeLa cells with pcDNA3.1
Myc/HisA vector (InVitrogen) containing β-TrCP or β-TrCP∆F.
Binding studies
Yeast two-hybrid binding analysis has been described previously
[S2,S4]. In vitro binding of purified Glu–Glu tagged β-catenin to in
vitro translated β-TrCP was carried out in 150 µl Triton lysis buffer con-
taining 1 µg β-catenin and 10 µl reticulocyte lysate in which radiola-
beled β-TrCP was produced by in vitro transcription and translation
according to the manufacturer’s instructions (Promega). Following a
2 h incubation, β-catenin was recovered by immunoprecipitation with
antibody to the Glu–Glu epitope and the immunoprecipitates were
washed three times and analyzed for β-TrCP by fluorography of
SDS–polyacrylamide gels. The phosphorylation of β-catenin by GSK3β
was performed at 30°C for 15 min in 20 µl kinase buffer (20 mM Tris-
HCl, pH 7.5, 10 mM MgCl2, 2 mM dithiothreitol, 25 mM NaCl, 50 mM
ATP, 10% glycerol) containing 2.5 µg/ml recombinant GSK3β. Phos-
phatase treatment of β-catenin was performed with a 1:100 dilution of
lambda phosphatase (New England Biolabs) for 15 min at 30°C. 
Transactivation studies
The 293T cells were seeded in 12-well plates (1.50 × 105 cells per
well) and transfected with 0.5 µg Top-tk-Luci or Fop-tk-Luci plasmids
together with 0.5 µg of the indicated pcDNA3 expression vectors and
10 ng of an RSV-Renilla luciferase plasmid. Fugene reagent was used
for transfection (Boehringer Mannheim). Luciferase activity was mea-
sured 24 h after transfection and normalized to transfection efficiency
by measuring Renilla luciferase activity (Promega Dual-Luciferase
reporter assay system).
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